Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transition considerations for extended half‐life factor products

9 Apr 2015

Abstract excerpt

After years of anticipation and recent publication of pivotal clinical trials 1, 2, extended half-life (EHL) factor VIII (FVIII) and FIX products have arrived on the market, signalling potentially important advances in the treatment of haemophilia. Biogen-Idec's Fc-fusion technology products are currently the only licensed EHL products; however, products from other manufacturers and using alternate technology are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemophilia Treatment and Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 25855484
DOI: 10.1111/hae.12683

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transition considerations for extended half‐life factor productsPMID 25855484Read ↗

The long and short of it: using the new factor products.Semantic proximity Read ↗

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Semantic proximity Read ↗

Emerging therapies for hemophilia: controversies and unanswered questionsSemantic proximity Read ↗

Navigation of the Hemophilia Drug Choice-Paralysis: A Quick User Guide to New and Existing TherapiesSemantic proximity Read ↗

Extending half-life in coagulation factors: where do we stand?Semantic proximity Read ↗

Emerging and future therapies for hemophiliaSemantic proximity Read ↗

Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.Semantic proximity Read ↗

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia ASemantic proximity Read ↗

Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.Semantic proximity Read ↗

Evolution of the Treatments for Hemophilia.Semantic proximity Read ↗

Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene TherapySemantic proximity Read ↗

The hope and reality of long‐acting hemophilia productsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.